Progress in cystic fibrosis and the CF Therapeutics Development Network

Area of Science:

• Medical Research
• Genetics
• Pulmonology

Background:

• Cystic fibrosis (CF) is a prevalent life-shortening genetic disorder affecting 70,000 people globally.
• The Cystic Fibrosis Foundation (CFF) established the CF Therapeutics Development Network (CF-TDN) in 1998 to expedite CF therapy development.
• The CF-TDN aims to accelerate the clinical evaluation of novel CF therapies.

Purpose of the Study:

• To review recent and significant research endeavors undertaken by the CF-TDN.
• To summarize the network's contributions to various therapeutic areas and biomarker development.
• To highlight the CF-TDN's role in advancing the CFF's mission to control and cure CF.

Main Methods:

• The review synthesizes data from 75 clinical trials conducted by the CF-TDN since its inception.
• It includes contributions to safety, proof-of-concept, and pivotal regulatory trials.
• Focus is placed on studies involving CFTR modulators, airway surface liquid hydrators, mucus modifiers, anti-infectives, anti-inflammatories, and nutritional therapies.

Main Results:

• The CF-TDN has significantly contributed to the evaluation of CFTR modulators, airway surface liquid hydrators, and mucus modifiers.
• The network has supported trials for anti-infectives, anti-inflammatories, and nutritional therapies.
• Advancements in CF biomarkers have been made to accelerate therapeutic development.

Conclusions:

• The CF-TDN has been instrumental in advancing the development of diverse CF therapies.
• The network's comprehensive approach, including biomarker research, is crucial for achieving the CFF's mission.
• Continued research and clinical trials through the CF-TDN are vital for controlling and curing cystic fibrosis.